Wellington Management Group LLP Buys 347,766 Shares of Zenas BioPharma, Inc. $ZBIO

Wellington Management Group LLP increased its stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO) by 27.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,593,819 shares of the company’s stock after buying an additional 347,766 shares during the quarter. Wellington Management Group LLP’s holdings in Zenas BioPharma were worth $40,451,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ZBIO. SR One Capital Management LP raised its position in Zenas BioPharma by 2.6% during the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after acquiring an additional 126,315 shares in the last quarter. NEA Management Company LLC grew its position in shares of Zenas BioPharma by 28.9% in the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after acquiring an additional 789,500 shares during the period. Federated Hermes Inc. increased its stake in shares of Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after purchasing an additional 853,740 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Zenas BioPharma during the 2nd quarter worth about $68,176,000. Finally, Vanguard Group Inc. raised its holdings in shares of Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after purchasing an additional 290,307 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ZBIO shares. Weiss Ratings downgraded shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Guggenheim reiterated a “buy” rating and set a $55.00 target price on shares of Zenas BioPharma in a research note on Friday, August 14th. Finally, Morgan Stanley boosted their target price on Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.71.

Zenas BioPharma Stock Performance

NASDAQ ZBIO opened at $32.88 on Friday. The stock has a market cap of $2.14 billion, a PE ratio of -3.66 and a beta of -1.04. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. The firm has a 50-day moving average of $30.61 and a 200-day moving average of $24.51. Zenas BioPharma, Inc. has a 52-week low of $13.50 and a 52-week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $15.00 million. On average, sell-side analysts anticipate that Zenas BioPharma, Inc. will post -5.81 EPS for the current year.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.